

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): June 23, 2003

**PROTEIN DESIGN LABS, INC.**  
(Exact name of registrant as specified in its charter)

---

---

Delaware  
(State or other jurisdiction of  
incorporation)

---

000-19756  
(Commission File Number)

---

94-3023969  
(IRS Employer Identification No.)

---

34801 Campus Drive  
Fremont, California 94555  
(Address of principal executive offices) (Zip Code)

---

Registrant's telephone number, including area code: (510) 574-1400

Not Applicable

(Former name or former address, if changed since last report)

***Item 5. Other Matters***

On June 23, 2003, Protein Design Labs, Inc. (the "Company") issued a press release updating the status of Genentech, Inc.'s humanization patent license arrangement with the Company.

The foregoing matter is discussed in greater detail in the Company's press release, a copy of which is attached hereto as Exhibit 99.1.

**Item 7. Financial Statements and Exhibits**

(c) Exhibits.

| <b><u>Exhibit No.</u></b> | <b><u>Description</u></b>          |
|---------------------------|------------------------------------|
| 99.1                      | Press Release dated June 23, 2003. |

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **PROTEIN DESIGN LABS, INC.**

Date: June 23, 2003

By: /s/ Glen Sato  
Glen Sato  
Senior Vice President and  
Chief Financial Officer

## INDEX TO EXHIBITS

**Exhibit**  
99.1

**Description**  
Press release dated June 23, 2003.